Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Abstract Plasma cell-free DNA (cfDNA) is a sensitive, noninvasive tool for monitoring the genomic landscape, heterogeneity, and evolution of cancer, aggregating genetic information from multiple metastatic sites. Here, we study 15,564 cfDNA samples from 12,827 patients with metastatic breast cancer (MBC). We classify samples, deep-sequenced with Guardant360, into MBC subtypes using our trained random forest model. Most patients have variants associated with therapeutic resistance and targetability of approved and experimental therapies, including in PIK3CA, ESR1, PTEN , and AKT1 . Frequencies of multiple actionable alterations differed from primary disease, and multiple variants per gene suggest independent resistant clones. The large cohort size enables uncovering clonal co-behaviors, including co-existence and exclusivity of alleles and correlation of allele fractions. cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials. We envision this large collection of MBC cfDNA data as an invaluable resource for the design and planning of future clinical trials.

Authors

Publication Details

Journal
Nature Communications
Published
2026-09-22
DOI
https://doi.org/10.1038/s41467-026-75976-9
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Gad A. Getz, Steven Jay Isakoff, Mendy Miller, Beverly Moy et al.
Nature Communications
Cancer Genomics and Diagnostics
article

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Gad A. Getz, Steven Jay Isakoff, Mendy Miller, Beverly Moy, Laura M. Spring, Andrzej Niemierko, Justin Cha, Massimo Cristofanilli, Aditya Bardia, Neelima Vidula, Adam Brufsky, Leif William Ellisen, Lorenzo Gerratana, Ignaty Leshchiner, Lesli Ann Kiedrowski, Dejan Juric, Rebecca J. Nagy, Ben Ho Park, Andrew A. Davis, Seth A. Wander, Charles S. Dai, Arielle J. Medford, Ami Shah, Joyce O’Shaughnessy, Jennifer C. Keenan
article en

Abstract

Abstract Plasma cell-free DNA (cfDNA) is a sensitive, noninvasive tool for monitoring the genomic landscape, heterogeneity, and evolution of cancer, aggregating genetic information from multiple metastatic sites. Here, we study 15,564 cfDNA samples from 12,827 patients with metastatic breast cancer (MBC). We classify samples, deep-sequenced with Guardant360, into MBC subtypes using our trained random forest model. Most patients have variants associated with therapeutic resistance and targetability of approved and experimental therapies, including in PIK3CA, ESR1, PTEN , and AKT1 . Frequencies of multiple actionable alterations differed from primary disease, and multiple variants per gene suggest independent resistant clones. The large cohort size enables uncovering clonal co-behaviors, including co-existence and exclusivity of alleles and correlation of allele fractions. cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials. We envision this large collection of MBC cfDNA data as an invaluable resource for the design and planning of future clinical trials.

Nature Communications
Life in Land
Openalex Percentile: Top 14%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.